Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

Citations Over TimeTop 10% of 2010 papers

Abstract

A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular-modeling derived strategy. Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compounds via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 35b (vaniprevir, MK-7009), which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.

Related Papers

• → The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity(2017)28 cited
• → Structure-activity relationships of fluorene compounds inhibiting HCV variants(2019)4 cited
• → Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity(1996)31 cited
• → Establishment of NS3 tumor cell line expressing Hepatitis C virus Non-structural Protein 3 as valuable tool for HCV challenging in mice(2015)2 cited
• Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum(2007)